Emiko Naro, NP
Family · Skaneateles, NYNPI 1669967998
Payments from drug & device makers
Across 101 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$312
- Madrigal Pharmaceuticals$228
- AbbVie$214
- Pfizer$151
- GSK$151
- Novo Nordisk$141
- plus $972 from 24 others
What the payments were for
- Food & beverage$2,169100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $312 |
| Madrigal Pharmaceuticals | 9 | $228 |
| AbbVie | 11 | $214 |
| Pfizer | 9 | $151 |
| GSK | 7 | $151 |
| Novo Nordisk | 7 | $141 |
| Lilly USA, LLC | 6 | $95 |
| Exact Sciences | 5 | $84 |
| Merck | 4 | $81 |
| Amgen | 4 | $73 |
| Boehringer Ingelheim | 3 | $62 |
| Intuitive Surgical | 1 | $59 |
| Johnson & Johnson | 3 | $56 |
| Bayer | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Indivior Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 1 | $34 |
| Astellas Pharma US Inc | 1 | $31 |
| Theratechnologies Inc. | 1 | $30 |
| Corium, LLC | 3 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Mirum Pharmaceuticals, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $20 |
| Gilead | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Novartis | 1 | $14 |
How this compares
$2,169 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $102,157 |
| JardianceEmpagliflozin | 36 | $58,755 |
| MounjaroTirzepatide | 33 | $54,137 |
| EliquisApixaban | 22 | $36,661 |
| TrulicityDulaglutide | 13 | $25,291 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $14,992 |
| VascepaIcosapent Ethyl | 11 | $6,532 |
| Rosuvastatin Calcium | 464 | $6,113 |
| MyrbetriqMirabegron | 13 | $5,501 |
| SynthroidLevothyroxine Sodium | 53 | $3,455 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 75 | $2,212 |
| Atorvastatin Calcium | 160 | $1,835 |
| Levothyroxine Sodium | 148 | $1,667 |
| Pregabalin | 20 | $1,558 |
| Omeprazole | 124 | $1,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $141 | $102,15749 claims |
| Lilly USA, LLCMounjaro, Trulicity | $95 | $79,42846 claims |
| Boehringer IngelheimJardiance | $62 | $58,75536 claims |
| PfizerEliquis | $151 | $36,66122 claims |
| GSKTrelegy Ellipta | $151 | $14,99216 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $5,50113 claims |
| AbbVieSynthroid | $214 | $3,45553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.
Other family in Skaneateles
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.